

FORM PTO-1390 (REV 11-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 019815-000100US
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.51) <b>09/555446</b>
INTERNATIONAL APPLICATION NO. PCT/US98/25422	INTERNATIONAL FILING DATE November 30, 1998	PRIORITY DATE CLAIMED December 1, 1997	
TITLE OF INVENTION MULTIVALENT RECOMBINANT ANTIBODIES FOR TREATING HRV INFECTIONS			
APPLICANT(S) FOR DO/EO/US FANG FANG			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<ol style="list-style-type: none"> <li>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</li> <li>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1).</li> <li>4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.</li> <li>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> has been transmitted by the International Bureau.</li> <li>c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</li> </ol> </li> <li>6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)).</li> <li>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> <li>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</li> <li>b. <input type="checkbox"/> have been transmitted by the International Bureau.</li> <li>c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</li> <li>d. <input checked="" type="checkbox"/> have not been made and will not be made.</li> </ol> </li> <li>8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</li> <li>9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</li> <li>10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</li> </ol>			
Items 11. to 16. below concern document(s) or information included:			
<ol style="list-style-type: none"> <li>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</li> <li>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</li> <li>13. <input checked="" type="checkbox"/> A <b>FIRST</b> preliminary amendment. <input type="checkbox"/> A <b>SECOND</b> or <b>SUBSEQUENT</b> preliminary amendment.</li> <li>14. <input type="checkbox"/> A substitute specification.</li> <li>15. <input type="checkbox"/> A change of power of attorney and/or address letter.</li> <li>16. <input type="checkbox"/> Other items or information:</li> </ol>			

U.S. APPLICATION NO. (if known, see 37 CFR 1.5)

INTERNATIONAL APPLICATION NO.  
PCT/US98/25422ATTORNEY'S DOCKET NUMBER  
019815-000100US

09/555446

CALCULATIONS PTO USE ONLY

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)):

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO ..... \$970.00

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO ..... \$840.00

International preliminary examination fee (37 CFR 1.482) not paid to USPTO but  
international search fee (37 CFR 1.445(a)(2)) paid to USPTO ..... \$760.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
but all claims did not satisfy provisions of PCT Article 33(1)-(4) ..... \$670.00

International preliminary examination fee paid to USPTO (37 CFR 1.482)  
and all claims satisfied provisions of PCT Article 33(1)-(4) ..... \$96.00

ENTER APPROPRIATE BASIC FEE AMOUNT =

\$ 670

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(e)).

\$

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE
Total claims	18 - 20 =		X \$18.00
Independent claims	11 - 3 =	+8	X \$78.00

\$

\$624

MULTIPLE DEPENDENT CLAIM(S) (if applicable)

+ \$260.00

\$

TOTAL OF ABOVE CALCULATIONS =

\$1,294

Reduction of 1/2 for filing by small entity, if applicable. A Small Entity Statement  
must also be filed (Note 37 CFR 1.9, 1.27, 1.28).

\$

SUBTOTAL =

\$

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

\$

+

TOTAL NATIONAL FEE =

\$ 1,294

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property

+

\$

TOTAL FEES ENCLOSED =

\$ 1,294

Amount to be:  
refunded

\$

charged

\$

a. ☐ A check in the amount of \$\_\_\_\_\_ to cover the above fees is enclosed.

b. ☒ Please charge my Deposit Account No. 20-1430 in the amount of \$ 1,294 to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. 20-1430. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

Kenneth A. Weber  
Townsend and Townsend and Crew LLP  
Two Embarcadero Center, 8th fl.  
San Francisco, CA 94111

SIGNATURE:

Kenneth A. Weber

NAME

31,677

REGISTRATION NUMBER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. National Phase of  
PCT/US98/25422 of:

FANG FANG

PRELIMINARY AMENDMENT

Application No.: Not yet assigned

Filed: Herewith

For: MULTIVALENT RECOMBINANT  
ANTIBODIES FOR TREATING HRV  
INFECTIONS

San Francisco, CA 94111  
May 31, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Prior to examination of the above-referenced application, please enter the  
following amendments and remarks.

IN THE CLAIMS:

Please cancel claims 1-6, 11, 12, 17, 18, 21-26, 30 and 34 from this application.

REMARKS

Upon cancellation of the aforementioned claims, claims 7-10, 13-16, 19-20, 27-  
29, 31-33 and 35-36 remain pending in this application.

Respectfully submitted,



Kenneth A. Weber  
Reg. No. 31,677

TOWNSEND and TOWNSEND and CREW LLP  
Two Embarcadero Center, 8<sup>th</sup> Floor  
San Francisco, California 94111-3834  
Tel: (415) 576-0200; Fax: (415) 576-0300  
KAW/tp  
SF 1101393 v1

009180-5445560

S P E C I F I C A T I O N

MULTIVALENT RECOMBINANT ANTIBODIES FOR TREATING HRV INFECTIONS

PRIORITY CLAIMS

5        This application claims the priority benefit of three U.S. Provisional Applications by Fang Fang: 60/067,119 filed December 1, 1997, 60/083,046 filed April 24, 1998, and 60/090,632 filed June 25, 1998, all of which are incorporated by reference herein.

FIELD OF THE INVENTION

10        This invention relates to high affinity multivalent recombinant antibodies, multivalent peptides, and their use in preventing and treating viral infections and related diseases.

BACKGROUND OF THE INVENTION

15        Human rhinoviruses (HRV) are among the most frequently occurring human pathogens. HRV are responsible for majority cases of the common cold (Stanway, G. 1994, "Rhino viruses". In: Webster R. G. (eds) Encyclopedia of Virology, New York: Academic Press, pp. 1253-1259; Sperber, S. J. and Hayden, F. G. 1988, Antimicrob. Agents Chemother. 32:409-419). In addition, HRV are a leading cause of upper respiratory tract infection and otitis media, *i.e.*, ear infection (Arola, M. *et al.*, 1990, Pedia 86:848-855).

20        Recurrent acute otitis media (AOM) is a prevalent infectious disease among young children and results in more than 8 million pediatric office visits each year. Teele *et al.*, 1989, J. Infect Dis. 160:83-94 found that 62% of children at age one have had at least one episode of AOM and 17% have had three or more. By age three, more than 80% of children have experienced otitis media and more than 40% have had three or more episodes. The  
25        annual treatment costs for AOM has been estimated at more than \$3.5 billion in the United States (Stool, S. E, and Field, M. J., 1989, Pediatr. Infect Dis. J. 8:S11-14).

30        At least 115 distinct serotypes of HRV have been reported (Uncapher *et al.*, 1991, Virology 180:814-817). Because of the large number of HRV serotypes, little immunological protection is afforded to a human subject by prior exposure to one or a few heterologous serotypes. The genetic heterogeneity of HRV accounts for the high incidence of rhinovirus infection.

Commercially available drugs only treat the symptoms of the common cold and AOM. They can not prevent rhinovirus infections. Prophylactics for the common cold are desirable, especially for young children who are most susceptible to the common cold and ear infections.

5

### SUMMARY OF THE INVENTION

The present invention relates to the generation of high affinity multivalent recombinant antibodies and multivalent peptides that bind to cellular receptors for rhinovirus and especially HRV. Specifically, it is directed to multivalent recombinant antibodies and multivalent peptides against the HRV binding sites on human ICAM-1 and LDL receptor molecules. This invention also relates to methods of using these antibodies and peptides to block the receptors so as to prevent and treat HRV infections and associated diseases and pathological conditions, including, but not limited to, the common cold, otitis media, asthma, bronchitis and sinusitis.

10

15

A "human rhinovirus" is accorded the definition provided in Hamparian *et al.*, 1987, Virology 159:191-192, and specifically includes all human serotypes of rhinovirus catalogued in Hamparian *et al.*, 1987, Virology 159:191-192, and additional serotypes of HRV which have been identified and will be identified thereafter.

20

A "recombinant antibody" in this invention contains the heavy chain variable domain ( $V_H$ ) and light chain variable domain ( $V_L$ ) of an antibody linked together in a single chain. The recombinant antibody specifically recognizes a cellular receptor for HRV, including, but not limited to, the major receptor ICAM-1 and the minor receptor LDLR, and reduces or prevents binding of HRV to human host cells.

25

A "multivalent recombinant antibody" in this invention includes any multimeric configuration of two or more, and especially three or more recombinant antibodies. Specifically, it includes bivalent, trivalent, tetravalent and pentavalent recombinant antibodies. In a preferred embodiment, multiple antigen binding domains are coupled to an inert polymer support, including, but not limited to, nitrocellulose, PVDF, DEAE, amino dextran, and lipid polymers. In another preferred embodiment, the multivalent antibody contains multiple units polymerized through their polymerization domains. Each unit contains a Fv fragment and a polymerization domain linked together (preferably expressed as a single chain polypeptide). The polymerization domains are capable of binding to each other by virtual of containing one or more peptide fragments having affinity for other peptide

30

fragments of the same or substantially the same amino acid sequence. The polymerization domain determines the configuration of the multimeric protein complex (*e.g.*, as dimer, trimer, tetramer, pentamer, or others). Examples of polymerization domains include, but are not limited to, coiled-coil domains such as described and defined in Lupas *et al.*, 1991, *Science* 252:1162-1164, and alpha-helical sequences such as described in Eisenberg, D. *et al.*, (1986) *Protein* 1:16-22, Ho and DeGrado (1987) *J.A.Chem.Soc.* 109:6751-6758, Regan and DeGrado, (1988) *Science* 241:976-978, and Hill *et al.*, (1990) *Science* 249:543-546. A polymerization domain can be a naturally occurring peptide or can be designed and synthesized artificially. A naturally occurring polymerization domain may be modified to generate other polymerization domains (*see, e.g.*, methods described in Harbury *et al.* *Science* 262:1401-1407, 1993). In even more preferred embodiments, the coiled-coil domain comes from the leucine zipper region of transcription factor GCN4, the tetramerization domain of p53, or the N-terminal residues (aa 20-80) of cartilage oligomeric matrix protein (*i.e.*, COMP). In another even more preferred embodiment, the alpha-helical sequences contain single helices or helix-turn-helix as summarized in Plückthun and Pack, (1997) *Immunotechnology* 3:83-105, incorporated by reference herein. The antigen binding sites or scFv fragments recognize cellular receptors for rhinoviruses, including, but not limited to, ICAM-1, LDL receptor and its related protein  $\alpha$ MR/LRP. In preferred embodiments, they recognize the rhinovirus binding sites on ICAM-1 and LDL receptor. The antigen binding sites or scFv fragments of a multivalent recombinant antibodies may recognize the same target (*e.g.*, either ICAM-1 or LDLR) or two or more different targets (*e.g.*, some recognize ICAM-1 while others recognize LDLR).

A "multivalent peptide" in this invention includes any multimeric configuration of two or more, and especially three or more peptides. Specifically, it includes bivalent, trivalent, tetravalent and pentavalent peptides. In a preferred embodiment, multiple antigen binding domains are coupled to an inert polymer support, including, but not limited to, nitrocellulose, PVDF, DEAE, amino dextran, and lipid polymers. In a second preferred embodiment, the multivalent peptides are in the form of tandem repeats in which peptides are joined directly or via linker sequences (*e.g.*, by recombinant DNA technology). In a third preferred embodiment, the multivalent peptide contains multiple units polymerized through their polymerization domains. Each unit contains a single peptide (or peptides in tandem repeats) and a polymerization domain linked together (preferably expressed as a single chain polypeptide). The polymerization domains are capable of binding to each other by virtual of

containing one or more peptide fragments having affinity for other peptide fragments of the same or substantially the same amino acid sequence. The polymerization domain determines the configuration of the multimeric protein complex (*e.g.*, as dimer, trimer, tetramer, pentamer, or others). Examples of polymerization domains include, but are not limited to, coiled-coil domains such as described and defined in Lupas *et al.*, 1991, Science 252:1162-1164, and alpha-helical sequences as described and defined in Eisenberg, D. *et al.*, (1986) Protein 1:16-22, Ho and DeGrado (1987) J.A.Chem.Soc. 109:6751-6758, Regan and DeGrado, (1988) Science 241:976-978, and Hill *et al.*, (1990) Science 249:543-546. A polymerization domain can be a naturally occurring peptide or can be designed and synthesized artificially. A naturally occurring polymerization domain may be modified to generate other polymerization domains (*see* Harbury *et al.* Science 262:1401-1407, 1993). In even more preferred embodiments, the coiled-coil domain comes from the leucine zipper region of transcription factor GCN4, the tetramerization domain of p53, or the N-terminal residues (aa 20-80) of cartilage oligomeric matrix protein. In another even more preferred embodiment, the alpha-helical sequences contain single helices or helix-turn-helix as summarized in Plückthun and Pack, (1997) Immunotechnology 3:83-105, incorporated by reference herein.

HRV bind to ICAM-1 in four regions. In preferred embodiments, the multivalent peptides bind to three or more (preferably four or more) amino acids in the following regions of human ICAM-1. These are referred to as the target sequences or target peptides hereinafter:

- Target No. 1: Residues 1-5: QTSVS
- Target No. 2: Residues 24-29: SCDQPK
- Target No. 3: Residues 40-49: KELLPLGNNR
- Target No. 4: Residues 70-77: PDGQSTAK

The multivalent recombinant antibodies and peptides of this invention bind to cellular receptors for rhinovirus with high affinity. In a preferred embodiment, they have an apparent affinity constant for the cellular receptors of no less than  $10^8 \text{ M}^{-1}$ . In a further preferred embodiment, they have an apparent affinity constant for the cellular receptors of no less than  $10^9 \text{ M}^{-1}$ . In an even further preferred embodiment, they have an apparent affinity constant for the cellular receptors of no less than  $10^{10} \text{ M}^{-1}$ .

By "apparent affinity constant" is meant the ratio of  $[\text{Ab-Ag}]/[\text{Ab}][\text{Ag}]$  when the antibody-antigen binding reaction reaches equilibrium.  $[\text{Ab-Ag}]$ ,  $[\text{Ab}]$ ,  $[\text{Ag}]$  are the

concentrations of antibody-antigen complex, free antibody, and free antigen, respectively. The apparent affinity constant of multivalent peptides is measured in the same way as the antibodies.

This invention also features formulations containing a pharmaceutically effective amount of an aforesaid multivalent recombinant antibody or multivalent peptide and a pharmaceutically acceptable carrier.

By "pharmaceutically effective" is meant the ability to prevent, treat, reduce or cure rhinovirus infection or one or more clinical symptoms of rhinovirus infection.

In a preferred embodiment, the composition comprises an antibody having binding affinity for both ICAM-1 and LDLR and preferably a multivalent recombinant antibody (mvAb) having binding affinity for both ICAM-1 and LDLR.

In another preferred embodiment, the composition comprises a first mvAb having binding affinity for ICAM-1 and a second mvAb having binding affinity for LDLR.

In another preferred embodiment, the composition comprises peptides (preferably multivalent peptides) having binding affinity for two or more (or three or more) HRV binding regions in ICAM-1.

In yet another preferred embodiment, the composition comprises multivalent peptides having binding affinity for no more than two HRV binding regions in ICAM-1.

The above identified multivalent recombinant antibodies and multivalent peptides may be used to prevent and treat rhinovirus infections and associated diseases or pathological conditions in mammals, especially in humans, including, but not limited to, the common cold, otitis media, bronchitis and sinusitis. In addition, the multivalent recombinant antibodies and peptides against ICAM-1 can also be used to prevent the infection of other viruses that are known to bind to ICAM-1, such as Coxsackie A virus. Furthermore, the multivalent recombinant antibodies against ICAM-1 can be delivered intravenously to block the interaction between LFA-1 and ICAM-1 as a way to control the immunological response relating to inflammation.

Other features and advantages of the invention will be apparent from the following detailed description of the invention, and from the claims.



### DETAILED DESCRIPTION OF THE INVENTION

HRV infect human upper respiratory tract by attaching to and then entering the epithelial cells lining the nasal cavity and nasopharynx. The attachment is mediated by specific interaction between HRV virions and receptors on the surface of epithelial cells.

5       Based on their selection of cellular receptors, HRV are grouped into two families (except for HRV-87): the major group and the minor group (Uncapher *et al.*, 1991, Virology 180:814-817). The major group contains at least 91 serotypes, all of which recognize a receptor identified as the intercellular adhesion molecule 1 (ICAM-1) (Greve *et al.*, 1989, Cell 56:839-847; Staunton *et al.*, 1989, Cell 56:849-853; Tomassini, 1989, Proc. Natl. Acad. Sci. USA 86:4907-4911). The minor group contains about 10 serotypes, and their cellular  
10       receptor is the low-density lipoprotein receptor (LDLR) and a related protein "alpha-macroglobulin receptor/LDLR-related protein ( $\alpha$ MR/LRP) (Hofer *et al.*, 1994, Proc. Natl. Acad. Sci. USA 91:1839-1842).

ICAM-1 is a member of the immunoglobulin supergene family and contains five  
15       homologous immunoglobulin-like domains defined by amino acids 1-88, 89-185, 186-284, 285-385, and 386-453 (Staunton *et al.*, 1988, Cell 52:925-933). ICAM-1 is also the cell surface ligand for the lymphocyte function-associated antigen-1 (LFA-1). A soluble form of ICAM-1 has been detected in normal human serum (Rothlein *et al.*, 1991, J. Immunol. 147:3788-3793). The expression of ICAM-1 is upregulated by inflammatory cytokines in  
20       activated leukocytes, endothelium and epithelium. Two other homologous molecules, ICAM-2 and ICAM-3, have similar cellular distributions like ICAM-1 and also bind to LFA-1.

ICAM-1 has distinct binding sites for rhinovirus and LFA-1 (Staunton *et al.*, 1990, Cell 61:243-254). The rhinovirus-binding site has been mapped to the N-terminal Ig-like  
25       domain (amino acids 1-88) (Staunton *et al.*, 1990, Cell 61:243-254; McClelland *et al.*, 1990, Proc. Natl. Acad. Sci. USA 88:7993-7997).

The extracellular portion of the ICAM-1 molecule has five immunoglobulin-like domains (D1-D5). D1 contains the primary binding site for rhinoviruses as well as the binding site for its natural ligand, *i.e.*, lymphocyte function-associated antigen 1 (LFA-1).  
30       Distinct amino acid residues are involved in the binding of ICAM-1 to HRV and LFA-1. The HRV contacting sites in D1 include residues 1, 2, 24-29, 40-49, and 70-77 (Staunton *et al.* (1988) Cell 52:925-933; Staunton *et al.* (1990) Cell 11:243-254; McClelland *et al.* (1991)

Proc. Natl. Acad. Sci. USA 88:7993-7997; Lineberger *et al.* (1990) J. Virol 64:2582-2587; and Olson *et al.* (1993) Proc. Natl. Acad. Sci. USA 90:507-511).

The three-dimensional structure of D1-D2 portion of the ICAM-1 molecule has been revealed by Casasnovas *et al.* (1998) Proc. Natl. Acad. Sci. USA 95:4134-4139; and Bella *et al.* (1998) Proc. Natl. Acad. Sci. USA 95:4140-4145. The tip of ICAM-1 molecule has three loops: BC (aa 23-29), DE (aa 43-48) and FG (aa 69-72). The three loops penetrate deep into the canyon on the surface of HRV. Antibodies or peptides that bind to these regions of the ICAM-1 molecule may mask the HRV binding site and prevent HRV from binding to ICAM-1.

Whereas a single peptide may not have the affinity required to prevent the interaction between HRV and ICAM-1, multivalent peptides which bind to the HRV binding regions of human ICAM-1 molecule can be used to prevent HRV infection in human and prevent and treat the common cold. It has been shown that multivalency can increase the affinity of a peptide by  $10^5$ - $10^6$  times (Terskikh *et al.*, 1997, Proc. Natl. Acad. Sci. USA 94:1663-1668).

The physiological function of LDLR is to bind plasma LDL, a cholesterol transport protein, initiate the internalization of the LDL, and supply cholesterol to cells (Daniel *et al.*, 1983, J. Biol. Chem. 258:4606). The LDL receptors on the surface of nasal epithelial cells are probably of little importance to the normal physiological functions of these mucosal cells since the nasal mucosa usually do not have access to plasma LDL.

One strategy of preventing HRV infection is to administer soluble ICAM-1 and LDLR as decoys to mask the receptor binding sites of HRV (U.S. Patent Serial Nos. 5,589,453, 5,674,982 and 5,603,932). The soluble forms of ICAM-1 (sICAM-1) have been shown to inhibit virus-receptor binding and decrease the virus infectivity (Marlin *et al.*, 1990, Nature 344:70-72; Greve *et al.*, 1991, J. Virol. 65:6015-23). Nasal spray made with soluble ICAM-1 has been shown to protect chimpanzees against HRV challenge (Huguenel *et al.*, 1997, American J. Resp. Critical Care Med. 155(4):1206-10). However, the protection afforded by sICAM-1 is very short (approximately 30 minutes) because the interaction between sICAM-1 and HRV is weak and the mucociliary clearance mechanism removes sICAM-1 molecules rather quickly (Arruda *et al.*, 1992, Antimicrobial Agents and Chemotherapy 36:1186-91; Illum, 1991, Trend in Biotech 9:284-289). Such shortcomings limit the use of sICAM-1 as a prophylactic against HRV infections.

Another strategy for preventing HRV infection is to block the HRV binding site on ICAM-1 with a monoclonal antibody (mAb) (Lineberger *et al.*, 1990, J. Virol.

64:2582-2587). It has been shown that a monoclonal antibody against ICAM-1, 1A6, remained bound to ICAM-1 molecule for two days in a cell culture, and the association withstood multiple washes (Colonno *et al.*, 1989, in Molecular Aspects of Picornavirus Infection and Detection (Semler BL and Ehrenfeld E, eds) pp. 169-178, American Society for Microbiology, Washington, D.C.). No adverse effect on cellular functions was observed when a 1,000-fold excess of antibody against ICAM-1 was cultured with HeLa cells (Colonno *et al.*, 1986, J. Virol. 57:7-12). In addition, intranasal administration of the antibody ICAM-1 in chimpanzees for up to one year did not produce detectable local or systemic toxicity (Hayden *et al.*, 1988, Antiviral Res. 9:233-247). The same group also showed that intranasal administration of 1A6 (1 mg/subject in 10 applications, -3 to +36 hours) delayed the onset of rhinovirus colds in human volunteers by up to 2 days.

However, 1A6 did not reduce overall infection or illness rates (Hayden *et al.*, 1988, Antiviral Res. 9:233-247. Casasnovas *et al.*, 1995, J. Bio. Chem. 270:13216-24 showed that the dissociation rates were similar between mAbs/ICAM-1 and HRV/ICAM-1 ( $1.67 \times 10^{-3} \text{ s}^{-1}$ , translating to a  $t_{1/2}$  of receptor-ligand bond of 6.9 minutes).

A single chain antibody has been cloned from 1A6 and has been shown to be able to block the HRV infection of cultured cells albeit at an efficacy lower than that of the original mAb (Condra *et al.*, 1990, J. Bio. Chem. 265:2292-95).

This invention encompasses Applicant's appreciation that the prophylactic effect of 1A6 and its corresponding single chain mAb is limited by their functional affinity (avidity) to ICAM-1. It is imperative to decrease the dissociation rate of the receptor-antibody complex (as measured by  $K_d$ ) in order to increase the avidity of antibodies to cellular HRV receptors.

#### Preventing HRV infection with recombinant multivalent antibodies and/or multivalent peptides having high avidity for ICAM-1 and/or LDLR

Certain native proteins increase their affinity to ligands through multimeric complexes. For example, although individual IgG molecules bind the complement factor C1q at a low affinity (100 nM), the same IgG molecules in clusters bind C1q at much higher affinities (about 1 nM and 3 nM, respectively, for IgG dimers and tetramers, Male *et al.*, 1987, in Advanced Immunology, eds. Male, D., Champion, B. and Cooke, A. (Gower Medical, London), pp. 2.1-2.13.).

Within the scope of this invention, Applicant prepares multivalent recombinant antibodies and/or multivalent peptides against cellular receptors of rhinoviruses in order to

utilize multivalency to achieve high affinity to the receptors and to stabilize the association between the antibodies and the receptors by decreasing the dissociation rate. A recombinant antibody with four (tetravalent) or five (pentavalent) binding sites will have much higher avidity to its target than a monoclonal antibody (bivalent) or a single chain antibody (monovalent). Such multivalent recombinant antibodies against ICAM-1 and LDLR are much more effective in preventing HRV infection than monoclonal antibodies and single chain antibodies. Likewise, a pentavalent peptide has  $10^5$ - $10^6$  times higher avidity than a single peptide and will be able to block HRV binding sites on ICAM-1 much more effectively.

#### Methods of making multivalent recombinant antibodies and/or multivalent peptides

A multivalent recombinant antibody (mvAb) can be made by linking the antigen binding domain of an antibody (*e.g.*, a single chain Fv fragment (scFv)) with a protein domain which polymerizes automatically, including, but not be limited to, the coiled-coil sequences and alpha-helical sequences in proteins. The antigen binding domain and the polymerizing domain can be connected through a synthetic linker. Recombinant antibodies can also be multimerized by adsorption or chemical coupling to a support made of a variety of inert polymers, including, but not limited to, nitrocellulose, PVDF, DEAE, amino dextran, and lipid polymers. A multivalent recombinant antibody (mvAb) made by coiled-coil protein domains or alpha-helical domains can be further polymerized by coupling to inert polymers to prepare a molecular complex of higher avidity. Multivalent peptides can be made in a similar way as the multivalent antibodies by replacing the scFv fragment with either a single peptide or a tandem repeat of peptides.

Coiled-coil domains have been identified in more than 200 proteins in GenBank (Lupas *et al.*, 1991, Science 252:1162-1164), including the leucine zipper transcription factors and the cartilage oligomeric matrix protein (COMP). Coiled-coil proteins have a characteristic seven-residue repeat, and the seven positions are designated as *a* through *g*, (*a.b.c.d.e.f.g*)<sub>n</sub>, with hydrophobic residues at positions *a* and *d* and polar residues generally elsewhere.

The methods described and disclosed in the following references can be used for the purposes of this invention in making tetrameric and pentameric recombinant antibodies.

Harbury *et al.*, 1993, Science 262:1607-1407 prepared stable trimeric and tetrameric complexes through simultaneous changes in positions *a* and *d* of the seven-residue repeat in

the leucine zipper domain of a transcription factor GCN4 (a coiled-coil sequence). In addition, a parallel tetrameric-helix complex was formed when the hydrophobic residues in position a was changed to leucine and the leucine residues in position d was changed to isoleucine.

5           Pack *et al.*, 1995, J. Mol. Biol. 246:28-34 made a tetravalent miniantibody against phosphoryl choline in the periplasm of *E. coli* by linking a single-chain Fv fragment of phosphoryl choline-binding antibody to the modified leucine zipper domain of GCN4. This tetravalent miniantibody exhibited higher avidity than that of the bivalent construct.

          Rheinnecker *et al.*, 1996, J. Immunol. 157:2989-2997 made a tetravalent  
10 miniantibody against a tumor-associated carbohydrate antigen Lewis Y by linking the scFv fragment with the tetramerization domain of human transcription factor p53 (amino acid 319 to 360). The multivalency lowered the dissociation rate of antigen-antibody complex by more than two orders of magnitude.

          Cartilage oligomeric matrix protein (COMP) is a pentameric glycoprotein of the  
15 thrombospondin family found in cartilage and tendon. Self-association of COMP is achieved through the formation of a five-stranded  $\alpha$ -helical bundle that involves 64 N-terminal residues (from amino acid 20 to 83). The complex is further stabilized by the interchain disulfide bonds between cysteines 68 and 71 (Efimov *et al.*, 1996, Proteins 24:259-262).

          To increase the affinity of a synthetic peptide to its ligand, Terskish *et al.*, 1997, Proc.  
20 Natl. Acad. Sci. USA 94:1663-1668 prepared a pentameric multivalent binding molecule by linking the peptide with the coiled-coil assembly domain of the COMP (residues 26-80). This homopentamer exhibits an avidity to its ligand at a level that is  $2 \times 10^5$  folds higher than that of the original peptide.

          Therefore, a pentavalent recombinant antibody or a pentavalent peptide can be  
25 generated by linking the scFv fragment or a peptide with the coiled-coil domain of COMP.

#### Example 1: Preparation of Multivalent Recombinant Antibodies Against ICAM-1 and LDL Receptor

30

##### A. Amplification and purification of rhinoviruses

Rhinoviruses are grown, purified and assayed as previously described (Abraham, G. *et al.*, 1984, J. Virol., 51:340; Greve *et al.*, 1989, Cell 56:839-847; U.S. Patent 5,603,932).

They are plaques purified and isolated from lysates of infected HeLa cells by polyethylene glycol precipitation and sucrose gradient centrifugation. Purity of the viral preparation is assessed by SDS-PAGE analysis and electron microscopy. Infectivity is quantitated by a limiting dilution assay as described by Minor, P. D., Growth, assay and purification of picornaviruses, In Virology: A Practical Approach, B. W. J. Mahy, ed (Oxford: IRL Press), pp. 25-41.

Specifically, HRV14, HRV3, HRV2 and HRV49 are chosen for this study, and all can be obtained from American Tissue Culture Collection. HRV14 and HRV3 bind to the major receptor ICAM-1 while HRV2 and HRV49 bind to the minor receptor LDLR.

B. Generation of monoclonal antibody against ICAM-1 and LDLR

HeLa cells are used to immunize BALB/c mice because both ICAM-1 and LDL receptor are expressed on the surface thereof. The procedure is described in U.S. Patent 5,674,982. Alternatively, polypeptides containing the rhinovirus-binding domain of ICAM-1 or LDLR can be used to immunize mice.

Briefly,  $10^7$  HeLa cells in 0.5 ml of phosphate-buffered saline (PBS) are injected into the peritoneal cavity of the BALB/c mice three times at three-week intervals. Two weeks later the mice are bled and the sera are tested for their capacity to protect HeLa cells from being infected by HRV14 and HRV2. Positive mice are boosted by a final injection of  $10^7$  HeLa cells. Three days later, the spleen cells are fused with myeloma cells to produce hybridoma. This can be carried out through well-known techniques, such as those described in U.S. Patent 4,196,265 or in Harlow and Lane, 1988, Antibodies, A Laboratory Manual, Cold Spring Harbor Laboratory.

The hybridoma is then screened as described in U.S. Patent 5,674,982. Briefly, 100 ml of supernatant from each hybridoma clone is incubated with  $3 \times 10^4$  HeLa cells in 96-well plated for 1 hr at  $37^\circ\text{C}$ ; the cells are then washed with PBS, and a sufficient amount of HRV14 or HRV2 are added to give complete cytopathic effect in 24-36 hr. Wells that are protected from infection (positive) are scored at 36 hr. The corresponding positive hybridoma are undergo several round of cloning by limiting dilutions in 96-wells until all of the hybridoma containing wells are positive.

ICAM-1 and LDLR used to raise antibody in this invention can be of any species origin as long as the antibody raised is able to reduce the binding of HRV to their human host cells.

- 5 C. Cloning the single chain Fv (scFv) region of the mAb and humanizing the antibody  
Single chain Fv fragments against ICAM-1 and LDLR are cloned from hybridomas against each antigen.

One way (a preferred way) of cloning the VH and VL fragments is to amplify them by polymerase chain reaction (PCR) from a hybridoma directed against ICAM-1 or LDLR.

- 10 Alternatively, the Fab fragment of the desired antibody can be cloned from a combinatorial immunoglobulin library in phage  $\lambda$  by panning using the purified ICAM-1 and LDLR as the antigens (Kang *et al.*, 1991, Methods 2:111-118; Barbas and Lerner, 1991, Methods 2:119-124). The polypeptides of VH and VL can be connected via a synthetic linker to form a single-chain Fv fragment (scFv), or one scFv fragment can dimerize with another to form  
15 either diabodies (Holliger *et al.*, 1993, Proc. Natl. Acad. Sci. USA 90:6444-6448) or chelating recombinant antibodies (CRAbs) (Neri *et al.*, 1995, J. Mol. Biol. 246:367-373).

- The amino acid sequences of the VH and VL domains can be modified based on the original antibody to increase the affinity to antigens or improve the yield of production in *E coli* or yeast. The origin of the antibody can be of any mammals, including, but are not  
20 limited to, human, mouse, rat and rabbit. When the original antibody is isolated from a species other than human, the VH and VL domains of the antibody can be humanized, such as using the methods in U.S. Patent 5,530,101.

- Total RNA is isolated from each hybridoma and is converted into cDNA by AMV reverse transcriptase. The VH and VL genes are amplified by PCR using different  
25 combinations of degenerate primers in the Ig-Primer kit (Novagen, WI) according to the manufacturer's protocol, or using the primers as described in Larrick & Fry, 1991, Methods 2:106-110. The resulting VH and VL fragments are cloned into a TA cloning vector (Invitrogen, CA) and sequenced. The sequences of multiple clones are compared and the consensus sequences are used to construct the scFv fragments. The VH and VL genes are  
30 linked by an artificial linker (GGGGS)<sub>3</sub> to form scFv fragment [VH-(GGGGS)<sub>3</sub>-VL] as in Batra *et al.*, 1990, and the scFv fragment is subcloned into a pBlueScript vector (Stratagene, CA). Methods of making svFv fragment are also described in U.S. Patents 5,571,894 and 5,608,039.

The cloned scFv sequence can be humanized to make it less immunogenic or nonimmunogenic to a human host. The humanization of antibody can be carried out as described in U.S. Patent 5,530,101. The sequences of scFv fragments can also be modified to increase the yield of production while still maintaining their antigenic specificity, such as changing the genetic codons or including a signal sequence as described in U.S. Patent 5,648,237.

D. Constructing multivalent recombinant antibody genes

Methods of making multivalent recombinant antibodies are summarized in Plückthun and Pack, (1997) Immunotechnology 3:83-105, incorporated by reference herein.

A pentavalent recombinant antibody is preferred. scFv fragments are linked with the pentamerization domain of COMP via a hinge region to give rise to the following fragment: scFv-hinge[(PQ)<sub>2</sub> PK(PQ)<sub>4</sub> PKPQPK(PE)<sub>2</sub>]-Pentamerization domain (COMP aa 28-72).

The pentamerization domain of COMP is amplified from plasmid p3b-COMP (Efimov *et al.*, 1994, FEBS letters 341:54-58) by PCR (Tomschy *et al.*, 1996, EMBO J. 14:3507-3514). The amino acid sequence of this COMP domain can be modified to increase the stability of the complex. For example, the Lys-29 and Ala-30 can be changed to cysteine residues (Terskish *et al.*, 1997, Proc. Natl. Acad. Sci. USA 94:1663-1668).

There are numerous sequences known to those skilled in the art as suitable for the hinge region. Therefore, the one listed here is only an example. The COMP pentamerization domain can be linked with the hinge and scFv by PCR and ligation using the standard molecular biology techniques. The whole fragment is subcloned into pTrc/His vector (Invitrogen, CA) to generate a bacteria expression plasmid pTrc/scFv-COMP.

E. Expressing multivalent recombinant antibodies in *E. coli*

The scFv-comp protein is expressed in *E. coli* as described in Terskish *et al.*, 1997, Proc. Natl. Acad. Sci. USA 94:1663-1668. Briefly, *E. coli* transformed with the plasmid pTrc/scFv-COMP is grown in culture until OD<sub>600</sub> = 0.5, then 1 mM isopropyl b-D-thiogalactoside is added to induce protein synthesis, followed by a 4 hr incubation at 30°C. Bacteria are harvested by centrifugation, lysed by three-rounds of freezing/thawing. The recombinant antibody protein is purified from the bacterial lysate by a nickel column (Qiagen).



The biological function of the multivalent recombinant antibodies (mvAb) is then examined by the receptor-binding assay and the cell protection assay described blow.

### Materials and Methods

- 5 1. The HRV major receptor ICAM-1 protein can be prepared from Hela cells as described in U.S. Patent 5,589,453. The minor receptor LDLR can be purified from Hela cells as described in U.S. Patent 5,603,932 or Schneider *et al.*, 1985, Methods Enzymology 109:405-417. Alternatively, soluble LDLR fragment can be expressed and purified from Sf9 insect cells as described in Marlovits *et al.*, (1998) FASEB 12:695-703.

2. Preparation of  $^{35}\text{S}$ -methionine labeled human rhinovirus serotypes 14 and 2 (HRV14 and HRV2)

The procedure is carried out as described in U.S. Patent 5,603,932. Briefly, four HeLa cell monolayers in  $165\text{cm}^2$  Petri dishes are infected with an MOI (multiplicity of infection) of 40 with HRV14 and HRV2 for 1 hr at  $34^{\circ}\text{C}$  in methionine-free MEM medium (Gibco) with 2% dialyzed fetal calf serum. The cells are then washed twice with PBS and incubated at  $34^{\circ}\text{C}$  in fresh medium.

After 3 hr, 1 mCi  $^{35}\text{S}$ -methionine (Amersham) is added to each monolayer and incubation is continued for 24 hr. The medium of the infected cells is then cleared by centrifugation for 30 min at 4,5000xg. The supernatant from the centrifugation is centrifuged for 2 hr at 140,000xg. The virus pellet is resuspended in Tris/EDTA and further purified over a 10-30% sucrose gradient. The individual fractions of the gradient are analyzed by 12% SDS-PAGE gel. The pure virus fractions are combined and stored in the presence of 1% bovine serum albumin (BSA) at  $4^{\circ}\text{C}$ .

3. Receptor Binding Assay

To demonstrate that the multivalent recombinant antibodies (mvAb) can block the binding of HRV to ICAM-1 and LDLR, various amount of mvAb is used in this assay to inhibit the binding of  $^{35}\text{S}$  HRV14 and  $^{35}\text{S}$  HRV2 to previously immobilized ICAM-1 and LDLR. This assay is based on the Solution Binding Assay described in U.S. Patent 5,674,982 with minor modifications. Purified ICAM-1 or LDLR is diluted in Tri/NaCl buffer

and allowed to adsorb to the walls of a microtiter plate. Each well of the microtiter plate is then further blocked with 10 mg/ml BSA and then washed with PBS. Specific mvAbs are diluted with 0.1% Triton X-100/1 mg/ml BSA/Tris/NaCl, added to each well precoated with either ICAM-1 or LDLR and allowed to incubate for 1 hr at 37<sup>0</sup>C. The same buffer without

5 mvAb is the positive control. The unbound mvAb is then washed off with PBS.

Approximately 20,000 cpm of <sup>35</sup>S HRV14 (to ICAM-1 precoated plates) and <sup>35</sup>S HRV2 (to LDLR precoated plates) are added to the each mvAb treated well and allowed to incubate for 1 hr at 37<sup>0</sup>C. The plates are washed and the bound radioactivity determined. Less

radioactivity in the mvAb treated wells is expected. Total inhibition of <sup>35</sup>S HRV binding can  
10 be achieved if enough mvAb is used to completely block the precoated ICAM-1 and LDLR.

#### 4. Cell protection assay

The assay described in Colonna *et al.*, 1986, J. Virol. 57:7-12 is used to demonstrate that mvAb against ICAM-1 and LDLR can protect host cells from HRV infection.

15 HeLa cells are plated in 48-well plates (Costar) at 1.5x10<sup>5</sup> cells per well and incubate over night to generate confluent monolayers. Duplicate monolayers are treated with various amount of each mvAb and incubated for 1 hr at 37<sup>0</sup>C. HRV14, HRV3, HRV2 and HRV49 are then applied to each well at MOI of 0.1 to 1 and allowed to incubate overnight at 37<sup>0</sup>C. The next day, monolayer is checked for cytopathic effect with a light microscope. Wells  
20 without the treatment of mvAbs but are infected by the HRV are used as controls. Less cytopathic effect is expected in the mvAb treated cells.

Some viruses other than HRV, such as Coxsackie A virus, also infect human host cells via ICAM-1. Therefore, the mvAbs against ICAM-1 can also offer protection against infection by these viruses. Such protective effect of mvAbs can be demonstrated by cell  
25 protection assay as described above by using a minimum amount of viruses needed to yield a cytopathic effect within 24 to 48 hours.

#### Example 2: Isolating human single chain antibodies (scFv) against ICAM-1 and LDLR from a human scFv phage display library

30 Vaughan *et al.* (1996) Nature Biotechnology 14:309-314 have successfully isolated several human single chain antibodies with high affinities from a phage display library

containing a repertoire of human scFv fragments. Human scFvs against ICAM-1 and LDLR can be isolated using similar strategy.

- i) Construction of human scFv library is carried out as described in Vaughan *et al.* (1996) Nature Biotechnology 14:309-314.

- ii) Isolating ICAM-1 and LDLR binding phage by panning

Human ICAM-1 or LDLR is diluted to a concentration of 20µg/ml and is used to coat immunotubes (Maxisorb, Nunc) by incubating for 1 h at 4°C. The remaining binding sites are saturated by bovine serum albumin (BSA). A portion of the amplified human scFv library ( $10^{13}$  phage) is first incubated for 2 h at 4°C in immunotubes precoated with 1mg/ml BSA. The phages unbound to BSA are transferred to the immunotubes precoated with human ICAM-1 or LDLR. After incubation for overnight at 4°C, the unbound phage are removed by washing 10 times with PBS buffer containing 0.5% Tween 20. The bound phages are eluted with 0.1M glycine buffer, pH 2.2, containing 1 mg/ml BSA. Four additional rounds are carried out in immunotubes coated with 5 µg/ml proteins. The panning protocols are also described in Griffiths *et al.* (1993) EMBO J. 12:725-734, and Hodits *et al.* (1995) J. Bio. Chem. 270:24078-24085, and Welply, J. K. *et al* (1996) Proteins 26:262-270.

Alternatively, mouse fibroblasts NIH3T3 which express human ICAM-1 or human LDLR will be established and used for panning. Specifically, a portion of the human scFv library is first incubated with parental NIH3T3 cells, the unbound phages are transferred to either NIH3T3-ICAM-1 cells or NIH3T3-LDLR cells. After incubation, the unbound phages are washed away, and the bound phages are amplified by infecting E. coli TG-1. The panning are performed for at least two more rounds.

- iii) Isolating protective clones against HRV infection

The ICAM-1 or LDLR binding phages are isolated from single ampicillin-resistant colonies of infected (suppressor) E. coli TG-1 using helper phage VCSM13 (Stratagene), and the phages are used to infect the (nonsuppressor) E. coli HB2151. Single ampicillin-resistant colonies are used to inoculated 200 µl of culture broth in microtiter plates, and the expression of soluble scFv fragments is induced by the addition of 1 mM isopropyl-b-D-thiogalactopyranoside to the culture (Griffiths, A. D. *et al.* (1993) EMBO J. 12:725-734, and Hodits *et al.* (1995) J. Bio. Chem. 270:24078-24085, and Welply *et al* (1996) Proteins

26:262-270). Bacteria are pelleted, supernatants containing scFv are collected, sterilized by filtration, and added to HeLa cells in cell protection assays as described previously. Clones giving rise to scFv which can protect HeLa cells from the cytopathic effects caused by HRV infection are selected, the encoding scFv regions are amplified via polymerase chain  
5 reactions from single colonies (Nissim *et al.* (1994) EMBO J. 13:692-698). The cloned human scFv genes are used to construct multivalent recombinant antibodies.

Alternatively, phage particles that carry scFv against HRV binding sites on either ICAM-1 or LDLR can be administered to human directly in nasal sprays as a way to prevent and/or treat the common cold.

10  
Example 3: Identifying binding peptides to the target sequences in human ICAM-1 by random peptide library

Random peptide libraries are constructed in phage fUSE5 vector as described previously (Scott, J. K. and Smith, G. P. (1990) Science 249:386-390). Construction and  
15 amplification of the libraries are also described in details in Smith, G. P. (1992) Cloning in fUSE vectors. Feb 10, 1992 ed. Division of Biological Sciences, University of Missouri, CO. and in Smith, G. P. & Scott, J. K. (1993) Methods Enzymol. 217:228-257.

Peptides which binds to the target sequences in human ICAM-1 are selected by panning:

20 Each of the target peptides is synthesized by a synthesizer, is diluted in PBS to a concentration of 20mg/ml and is used to coat 3.5 cm wells by incubating for 1 h at 4°C. The remaining binding sites are saturated by bovine serum albumin (BSA). A portion of the amplified random peptide library is first incubated for 2 h at 4°C in a 3.5 cm well precoated with 1 mg/ml BSA in PBS and 1 mM MnCl<sub>2</sub>. The phages unbound to BSA are transferred to  
25 a similar well precoated with a target peptide. After incubation for 1 h at 4°C, the unbound phage are removed by washing 10 times with PBS buffer containing 0.5% Tween 20. The bound phage is eluted with 0.1M glycine buffer, pH 2.2, containing 1 mg/ml BSA and 0.1 mg/ml phenol red. The phages are amplified using the K91kan bacteria and partially purified by precipitation with polyethylene glycol (Smith, G. P. (1992) Cloning in fUSE vectors. Feb  
30 10, 1992 ed. Division of Biological Sciences, University of Missouri, CO. and in Smith, G. P. & Scott, J. K. (1993) Methods Enzymol. 217:228-257). The panning is repeated for two more rounds.

Sequences carried by the selected phage are then determined using the Sequenase kit (United States Biochemical) with the primer 5'-CCCTCATAGTTAAGCGTAACG-3' (Koivunen, E. *et al.* (1993) J. Bio. Chem. 268:20205-20210).

5 Example 4: Identifying binding peptides to the target sequences in human ICAM-1 by molecular recognition theory and target complementary library technology (TCLT)

According to the molecular recognition theory, peptides with opposite hydropathic profiles bind to each other. One example is that a pair of peptides encoded by the sense and  
10 anti-sense strands of DNA bind to each other specifically (*see* Provisional Application Serial No. 60/083046 filed April 24, 1998, incorporated by reference herein in its entirety; and Blalock, J. E. (1990) TIBTECH 8:140-144), and they are known as complementary peptides.

Complementary peptides to the target sequences in human ICAM-1 are encoded by the antisense strand of human ICAM-1 gene in either 5'-3' or 3'-5' orientation. Therefore, for  
15 each target peptide, there are two complementary sequences, and both have specific affinity for the target peptide. The sequences of the complementary peptides for each target sequence in human ICAM-1 are listed in the following:

Target No. 1: VCRHR & GHRCL

Target No. 2: LGLVTG & RTLVGf

20 Target No. 3: PVVPRQEQLL & FLNEDGPLLA

Target No. 4: FSCSLPIR & GIPVSCRF

These complementary peptides (and their homologs) and peptides containing such may have the ability to bind to human ICAM-1 molecule at the target sequences.

The affinity of a complementary peptide to its target sequence can be improved by optimizing  
25 the peptide sequence via a computer program, or by selecting peptides from a target complementary peptide library as described in Provisional Application Serial No. 60/083046.

Example 5: Construction of multivalent peptides against human ICAM-1

One way of making a multivalent peptide is to link multiple copies of a single peptide  
30 or multiple copies of different peptides in tandem repeats to create molecules with the following structures:

[peptide A-(linker)-]<sub>n</sub> (n ≥ 2) or

[peptide A-(linker)-peptide B-(linker)-]<sub>n</sub> (n ≥ 2)

A linker can be of variable length and be composed by any amino acid residues. An alternative way of making a multivalent peptide is to link a single peptide or a peptide tandem repeat with a polymerization sequence derived from a coiled-coil protein. These molecules have the following structures:

5 peptide A--(hinge)--polymerization sequence--purification tag or [peptide A-(linker)-]<sub>n</sub>--polymerization sequence--purification tag

A pentavalent peptide is preferred. It can be constructed in the same way as the pentavalent recombinant antibody as described above. Once the nucleotide sequence encoding a peptide is known, those skilled in the art will be able to construct a gene of  
10 multivalent peptide in a fashion as described above .

The characterization and production of the multivalent peptide are carried out in the same fashion as the multivalent recombinant antibodies.

#### FORMULATION AND ADMINISTRATION

15 The antibodies and peptides of the present invention can be administered to a host alone, or in a pharmaceutical composition comprising the active compound and a carrier or excipient.

In accordance with this invention, the aforementioned multivalent recombinant antibodies and multivalent peptides can be administered to a subject for reducing or  
20 inhibiting rhinovirus infection. The antibodies and peptides are useful as a prophylaxis or means for treating disorders such as the common cold and AOM. The pharmaceutical compositions of the invention contain the antibodies or peptides in association with a compatible pharmaceutically acceptable carrier material.

Techniques for formulation and administration may be found in Remington's  
25 Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, PA (1990). Any conventional carrier material for topical administration can be utilized. Carriers or excipients can be used to facilitate administration of the compound, for example, to increase the solubility of the compound. Furthermore, the pharmaceutical preparations may contain other pharmaceutically active agents. Additional additives such as preservatives, stabilizers,  
30 emulsifying agents, buffers and the like may be added in accordance with accepted practices of pharmaceutical compounding.

Any conventional composition utilized for application to the nasal epithelium can be utilized in accordance with this invention. The aforementioned antibodies are preferably

prepared as sprays, ointments, tinctures, creams, gels, solutions, lotions, suspensions, and the like. The pharmaceutical preparations may be sterilized and/or may contain adjuvants such as preservatives, stabilizers, wetting agents, emulsifiers, salts for varying the osmotic pressure and/or buffers. They can be prepared by mixing the aforementioned active  
5 ingredient (*i.e.*, a pharmaceutically effective amount of a multivalent recombinant antibody) with non-toxic, therapeutically inert, solid or liquid carriers customarily used in such preparations.

Preferably, the topical solutions are contained in a pressurized bottle attached to a hand pump and the mvAbs or multivalent peptide is delivered to the nasal and  
10 nasopharyngeal mucosa as aerosols.

All publications referenced are incorporated by reference herein, including the nucleic acid sequences and amino acid sequences listed in each publication, and the drawings and tables in each publication. All the compounds disclosed and referred to in the publications mentioned above are incorporated by reference herein, including those compounds disclosed  
15 and referred to in articles cited by the publications mentioned above.

Other embodiments of this invention are disclosed in the following claims. As will be obvious to those skilled in the art, many variations and modifications may be made without departing from the spirit and scope of the invention.

What is claimed is:

1. A multivalent recombinant antibody against ICAM-1 and LDL receptor, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

2. The multivalent recombinant antibody of claim 1 comprising two or more antigen binding domains for ICAM-1 and two or more antigen binding domains for LDL receptor.

3. The multivalent recombinant antibody of claim 1 comprising three or more antigen binding domains for ICAM-1 and three or more antigen binding domains for LDL receptor.

4. The multivalent recombinant antibody of claim 1 comprising two or more first single chain Fv fragments against ICAM-1, two or more second single chain Fv fragments against LDL receptor, wherein each of said first single chain Fv fragments and said second single chain Fv fragments is linked to a polymerization domain.

5. The multivalent recombinant antibody of claim 4, wherein said polymerization domain comprises a coiled-coil sequence from transcription factor GCN4.

6. The multivalent recombinant antibody of claim 4, wherein said polymerization domain comprises a coiled-coil sequence from cartilage oligomeric matrix protein.

7. A multivalent recombinant antibody against ICAM-1, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$ .

8. The multivalent recombinant antibody of claim 7 comprising four or more antigen binding domains for ICAM-1.

9. The multivalent recombinant antibody of claim 7 comprising five or more antigen binding domains for ICAM-1.



10. The multivalent recombinant antibody of claim 7 comprising three or more single chain Fv fragments against ICAM-1 and each of said single chain Fv fragment is linked to a polymerization domain.

5 11. The multivalent recombinant antibody of claim 10, wherein said polymerization domain comprises a coiled-coil sequence from transcription factor GCN4.

10 12. The multivalent recombinant antibody of claim 10, wherein said polymerization domain comprises a coiled-coil sequence from cartilage oligomeric matrix protein.

13. A multivalent recombinant antibody against LDL receptor, wherein said antibody has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

15 14. The multivalent recombinant antibody of claim 13 comprising four or more antigen binding domains for LDL receptor.

20 15. The multivalent recombinant antibody of claim 13 comprising five or more antigen binding domains for LDL receptor.

25 16. The multivalent recombinant antibody of claim 13 comprising three or more single chain Fv fragments against LDL receptor and each of said single chain Fv fragment is linked to a polymerization domain.

30 17. The multivalent recombinant antibody of claim 16, wherein said polymerization domain comprises a coiled-coil sequence from transcription factor GCN4.

18. The multivalent recombinant antibody of claim 16, wherein said polymerization domain comprises a coiled-coil sequence from cartilage oligomeric matrix protein.

19. A topical formulation for preventing rhinovirus infection, comprising:

a pharmaceutically effective amount of a multivalent recombinant antibody against ICAM-1, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$ , and

a pharmaceutically acceptable carrier.

5

20. The topical formulation of claim 19, further comprising a multivalent recombinant antibody against LDL receptor, wherein said antibody has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

10

21. A topical formulation for preventing rhinovirus infection, comprising:  
a pharmaceutically effective amount of a multivalent recombinant antibody against ICAM-1 and LDL receptor, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ , and

15

a pharmaceutically acceptable carrier.

22. A method of preventing rhinovirus infection in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

20

23. A method of preventing rhinovirus infection in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$ .

25

24. A method of preventing rhinovirus infection in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

30

25. A method of preventing rhinovirus infection in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a first multivalent recombinant antibody and a second multivalent recombinant antibody, wherein said first antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8$   $M^{-1}$  and said second antibody has an apparent affinity constant for LDL receptor of no less than  $10^8$   $M^{-1}$ .

26. A method of preventing the common cold in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8$   $M^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8$   $M^{-1}$ .

27. A method of preventing the common cold in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8$   $M^{-1}$ .

28. A method of preventing the common cold in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for LDL receptor of no less than  $10^8$   $M^{-1}$ .

29. A method of preventing the common cold in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a first multivalent recombinant antibody and a second multivalent recombinant antibody, wherein said first antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8$   $M^{-1}$  and said second antibody has an apparent affinity constant for LDL receptor of no less than  $10^8$   $M^{-1}$ .

30. A method of preventing acute otitis media in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

31. A method of preventing acute otitis media in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$ .

32. A method of preventing acute otitis media in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a multivalent recombinant antibody, wherein said antibody has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

33. A method of preventing acute otitis media in a host, comprising the step of administering to the nasal epithelium of said host a pharmaceutically effective amount of a first multivalent recombinant antibody and a second multivalent recombinant antibody, wherein said first antibody has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and said second antibody has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

34. A multivalent peptide against ICAM-1 and LDL receptor, wherein said multivalent peptide has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$  and an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

35. A multivalent peptide against ICAM-1, wherein said multivalent peptide has an apparent affinity constant for ICAM-1 of no less than  $10^8 \text{ M}^{-1}$ .

36. A multivalent peptide against LDL receptor, wherein said multivalent peptide has an apparent affinity constant for LDL receptor of no less than  $10^8 \text{ M}^{-1}$ .

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032  
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>DECLARATION FOR UTILITY OR DESIGN PATENT APPLICATION (37 CFR 1.63)</b>  <input type="checkbox"/> Declaration Submitted with Initial Filing  <input checked="" type="checkbox"/> Declaration Submitted after Initial Filing (surcharge (37 CFR 1.16 (e)) required)	Attorney Docket Number	019815-000100US
	First Named Inventor	Fang Fang
	<b>COMPLETE IF KNOWN</b>	
	Application Number	09/555,446
	Filing Date	
	Group Art Unit	
	Examiner Name	

As a below named inventor, I hereby declare that:

My residence, post office address, and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

MULTIVALENT RECOMBINANT ANTIBODIES FOR TREATING HRV INFECTIONS

the specification of which

(Title of the Invention)

☐ is attached hereto  
OR

☒ was filed on (MM/DD/YYYY) November 30, 1998 as United States Application Number or PCT International

Application Number PCT/US98/25422 and was amended on (MM/DD/YYYY) (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment specifically referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56.

I hereby claim foreign priority benefits under 35 U.S.C. 119(a)-(d) or 365(b) of any foreign application(s) for patent or inventor's certificate, or 365(a) of any PCT international application which designated at least one country other than the United States of America, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or of any PCT international application having a filing date before that of the application on which priority is claimed.

Prior Foreign Application Number(s)	Country	Foreign Filing Date (MM/DD/YYYY)	Priority Not Claimed	Certified Copy Attached?	
				YES	NO
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
			<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

☐ Additional foreign application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto:

I hereby claim the benefit under 35 U.S.C. 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)	<input type="checkbox"/> Additional provisional application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.
60/067,119	12/1/1997	
60/083,046	4/24/1998	
60/090,632	6/25/1998	

[Page 1 of 2]

Burden Hour Statement: This form is estimated to take 0.4 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/01 (12-97)

Approved for use through 9/30/00. OMB 0651-0032

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

## DECLARATION — Utility or Design Patent Application

I hereby claim the benefit under 35 U.S.C. 120 of any United States application(s), or 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application in the manner provided by the first paragraph of 35 U.S.C. 112, I acknowledge the duty to disclose information which is material to patentability as defined in 37 CFR 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application.

U.S. Parent Application or PCT Parent Number	Parent Filing Date (MM/DD/YYYY)	Parent Patent Number (if applicable)

☐ Additional U.S. or PCT international application numbers are listed on a supplemental priority data sheet PTO/SB/02B attached hereto.

As a named inventor, I hereby appoint the following registered practitioner(s) to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith:

☐ Customer Number  OR  
☒ Registered practitioner(s) name/registration number listed below

Place Customer  
Number Bar Code  
Label here

Name	Registration Number	Name	Registration Number
Kenneth A. Weber	31,677		

☐ Additional registered practitioner(s) named on supplemental Registered Practitioner Information sheet PTO/SB/02C attached hereto.


Direct all correspondence to: ☐ Customer Number  OR ☒ Correspondence address below

Name	Kenneth A. Weber				
Address	Townsend and Townsend and Crew LLP				
Address	Two Embarcadero Center, 8th fl.				
City	San Francisco	State	CA	ZIP	94111
Country	US	Telephone	415-576-0200	Fax	415-576-0300

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001 and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Name of Sole or First Inventor:

☐ A petition has been filed for this unsigned inventor

Given Name (first and middle (if any))		Family Name or Surname					
Fang		Fang					
Inventor's Signature					Date	8/4/00	
Residence: City	San Diego	State	CA	Country	US	Citizenship	CN
Post Office Address	7155-B Calabria Court						
Post Office Address							
City	San Diego	State	CA	ZIP	92122	Country	US

☐ Additional inventors are being named on the \_\_\_\_\_ supplemental Additional Inventor(s) sheet(s) PTO/SB/02A attached hereto